NCT06341595View on ClinicalTrials.gov

Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM

PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Gastric CancerGastric Cancer Metastatic to Regional Lymph Nodes
Interventions
DRUG

Sintilimab

Sintilimab: 200mg iv q3w d1, 4-6 cycles

RADIATION

Extraperitoneal radiation therapy

Radiotherapy using extraperitoneal radiation therapy, once a day, 5 times a week, 1.8-2 Gy/f, a total of 45-50.4 Gy (lymph node lesion radiation dose of 60-66 Gy)

DRUG

Oxaliplatin

oxaliplatin: 130mg/m\^2, D1, Q3W, 4-6 cycles

DRUG

S-1

S-1: 40mg/m\^2, bid, d1-14, 4-6 cycles

Trial Locations (1)

210029

RECRUITING

Jiangsu Province Hospital, Nanjing

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER